Munich Startup
RNATICS GmbH

RNATICS GmbH

Founded2021
Business ModelB2B
IndustryBioTech
This content was machine translated.

About RNATICS GmbH

RNATICS develops medicines based on short nucleic acid molecules, so-called oligonucleotides, that target disease-causing RNAs in tissue-resident macrophages. This novel delivery mechanism enables access to organs that have previously been inaccessible for nucleic acid therapies, opening up significant therapeutic potential in many diseases. We plan to start the first clinical trial (Phase I) of our lead candidate, RCS-21, for the treatment of fibrotic lung disease following viral infections (e.g. COVID-19) in spring 2024.

More like this

Discover more articles, startups, and events from the ecosystem

Munich Startup Recap 43/26
Ecosystem

Munich Startup Recap 43/26

25.10.26
2 Min.
GoCircular Munich: A Map for Munich’s Circular Economy
Ecosystem

GoCircular Munich: A Map for Munich’s Circular Economy

23.10.26
3 Min.
Ahron: The Future of HR? Fewer Clicks, More People
Interviews

Ahron: The Future of HR? Fewer Clicks, More People

23.10.26
4 Min.